Charles Bennett to Clinical Trials as Topic
This is a "connection" page, showing publications Charles Bennett has written about Clinical Trials as Topic.
Connection Strength
2.200
-
Reply to W. Read. J Clin Oncol. 2014 Feb 20; 32(6):604-5.
Score: 0.328
-
Finishing the picture: problems with public reporting of clinical trials. J Clin Oncol. 2013 Aug 20; 31(24):2981-2.
Score: 0.318
-
Upping recruitment in clinical trials: are the costs worth it? Onkologie. 2009 Jul; 32(7):378-9.
Score: 0.239
-
Clinical trials: are they a good buy? J Clin Oncol. 2001 Dec 01; 19(23):4330-9.
Score: 0.142
-
Evaluating the financial impact of clinical trials in oncology: results from a pilot study from the Association of American Cancer Institutes/Northwestern University clinical trials costs and charges project. J Clin Oncol. 2000 Aug; 18(15):2805-10.
Score: 0.129
-
Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA. 1999 Oct 20; 282(15):1453-7.
Score: 0.123
-
Economic analyses in clinical trials for cooperative groups: operational considerations. Cancer Invest. 1997; 15(5):448-53.
Score: 0.101
-
Interpretation of surrogate endpoints in the era of the 21st Century Cures Act. BMJ. 2016 Dec 30; 355:i6286.
Score: 0.101
-
Evaluation of gemtuzumab ozogamycin associated sinusoidal obstructive syndrome: Findings from an academic pharmacovigilance program review and a pharmaceutical sponsored registry. Leuk Res. 2016 May; 44:61-4.
Score: 0.096
-
Cost-effectiveness models of clinical trials of new pharmaceuticals for AIDS-related Pneumocystis carinii pneumonia: are they helpful to policy makers? Clin Perform Qual Health Care. 1995 Jul-Sep; 3(3):156-64.
Score: 0.091
-
Economic analyses of clinical trials in cancer: are they helpful to policy makers? Stem Cells. 1994 Jul; 12(4):424-9.
Score: 0.085
-
Epileptogenic potential of carbapenem agents: mechanism of action, seizure rates, and clinical considerations. Pharmacotherapy. 2011 Apr; 31(4):408-23.
Score: 0.068
-
Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylate. Clin Cancer Res. 2009 Jun 01; 15(11):3850-5.
Score: 0.060
-
Cost considerations in the management of cancer in the older patient. Oncology (Williston Park). 2007 Jun; 21(7):851-7; discussion 858, 860, 862 passim.
Score: 0.052
-
Systematic review of piperacillin-induced neutropenia. Drug Saf. 2007; 30(4):295-306.
Score: 0.050
-
Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol. 2006 Dec; 135(5):642-50.
Score: 0.050
-
Reducing adverse drug events in the outpatient chemotherapy setting: attention must be paid. Cancer. 2005 Dec 01; 104(11):2289-91.
Score: 0.047
-
Single-arm clinical trials that supported FDA accelerated approvals have modest effect sizes and were at high risk of bias. J Clin Epidemiol. 2022 08; 148:193-195.
Score: 0.036
-
Cost analyses of adjunct colony stimulating factors for acute leukemia: can they improve clinical decision making. Leuk Lymphoma. 2000 Mar; 37(1-2):65-70.
Score: 0.031
-
Comparing cost-effectiveness analyses for the clinical oncology setting: the example of the Gynecologic Oncology Group 111 trial. Cancer Invest. 2000; 18(3):261-8.
Score: 0.031
-
Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol. 2008 Jan 01; 26(1):132-49.
Score: 0.013
-
Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood. 2002 Oct 01; 100(7):2303-20.
Score: 0.009